EGR1 and neuroblastoma: Similar ChIP‐qPCR experiments using Pol II antibody also showed an approximately threefold decrease in Pol II occupancy at the Egr1 promoter in Med23−/− cells relative to WT cells.[25] This reduction in Egr1 persisted regardless of serum induction.[26] Similarly, in Hela cells with siRNA‐mediated knockdown of MED14 and in a human neuroblastoma cell line with CRISPR/Cas9‐mediated knockdown of MED12, serum‐induced EGR1 and FOS mRNA levels were both downregulated.